The table below shows Compass Therapeutics, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q1 2025
Q1 2024
Q1 2023
Q1 2022
Q1 2021
Operating cash flow
-$17.27M
-$13.21M
-$13.89M
-$12.23M
-$7.94M
-$5.61M
Capital expenditure
$82.00K
$18.00K
$0.00
$0.00
$194.00K
$128.00K
Investing cash flow
$38.43M
$11.59M
-$4.10M
$4.27M
-$193.00K
-$13.00K
Dividends paid
-
-
-
-
CMPX operating cash flow (10-K history)
Compass Therapeutics, Inc. reported operating cash flow of -$49.14M for fiscal year 2025. That is down 9.6% from -$44.85M in fiscal 2024. Over the 8 fiscal years shown, operating cash flow declined from -$32.76K (FY 2019) to -$49.14M. Figures come from the company's audited annual reports as filed with the SEC.